APA (7th ed.) Citation

CJ, O., BN, R., BS, B., DK, B., JW, C., KK, C., . . . L, Z. (2010). Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: Synthesis, SAR development, and in vivo efficacy in cognition models. Journal of medicinal chemistry, 53(3), 1222. https://doi.org/10.1021/jm9015075

Chicago Style (17th ed.) Citation

CJ, O'Donnell, et al. "Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel Alpha 7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models." Journal of Medicinal Chemistry 53, no. 3 (2010): 1222. https://doi.org/10.1021/jm9015075.

MLA (9th ed.) Citation

CJ, O'Donnell, et al. "Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel Alpha 7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models." Journal of Medicinal Chemistry, vol. 53, no. 3, 2010, p. 1222, https://doi.org/10.1021/jm9015075.